Host deletion of Mertk decreased tumor burden and/or prolonged survival in immunocompetent and syngeneic mouse models of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) [65,66,67]. This evidence concerns the gene MERTK and neoplasm.